Compounds > pomalidomide
Page last updated: 2024-09-04

pomalidomide and Peripheral Nerve Diseases

pomalidomide has been researched along with Peripheral Nerve Diseases in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cavo, M; Davies, FE; Delforge, M; Dimopoulos, MA; Facon, T; Hansson, M; Leleu, X; Ludwig, H; Mateos, MV; Miguel, JF; Moreau, P; Morgan, GJ; Palumbo, A; Schey, SA; Sonneveld, P; Weisel, K; Zweegman, S1
Anderson, KC; Dimopoulos, MA; Moreau, P; Richardson, PG1
Colson, K1
Lentzsch, S; Raza, S; Safyan, RA1
Iida, S1

Reviews

5 review(s) available for pomalidomide and Peripheral Nerve Diseases

ArticleYear
Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma.
    Leukemia, 2014, Volume: 28, Issue:8

    Topics: Age Factors; Clinical Trials as Topic; Dexamethasone; Drug Administration Schedule; Humans; Immunologic Factors; Infections; Multiple Myeloma; Neutropenia; Peripheral Nervous System Diseases; Quality of Life; Thalidomide; Venous Thromboembolism

2014
Current treatment landscape for relapsed and/or refractory multiple myeloma.
    Nature reviews. Clinical oncology, 2015, Volume: 12, Issue:1

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulins; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Peripheral Nervous System Diseases; Pyrazines; Thalidomide; Treatment Outcome

2015
Treatment-related symptom management in patients with multiple myeloma: a review.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2015, Volume: 23, Issue:5

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug-Related Side Effects and Adverse Reactions; Humans; Immunologic Factors; Immunomodulation; Lenalidomide; Multiple Myeloma; Oligopeptides; Peripheral Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Quality of Life; Thalidomide

2015
Immunomodulatory Drugs (IMiDs) in Multiple Myeloma.
    Current cancer drug targets, 2017, Volume: 17, Issue:9

    Topics: Clinical Trials as Topic; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Peripheral Nervous System Diseases; Proteasome Inhibitors; Quality of Life; Thalidomide; Venous Thromboembolism

2017
[Multiple myeloma].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2012, Volume: 53, Issue:2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Denosumab; Diphosphonates; Humans; Imidazoles; Melphalan; Multiple Myeloma; Peripheral Nervous System Diseases; Prednisolone; Pyrazines; Randomized Controlled Trials as Topic; Thalidomide; Zoledronic Acid

2012